Oral retinoids and plasma lipids

Jessica S. Lilley, Macrae F. Linton, Sergio Fazio

    Research output: Contribution to journalArticle

    14 Scopus citations


    Retinoids and rexinoids are prescribed for conditions ranging from acne vulgaris to hyperkeratosis to cutaneous T cell lymphoma. Dyslipidemia is a frequent consequence of the use of these drugs, with more than one-third of patients manifesting aberrations in triglyceride (TG) levels. The efficacy of retinoic acid derivatives is linked to their influence on lipid metabolism in the skin, which can impair systemic lipid trafficking and metabolism in some patients. Thus, baseline screening for preexisting dyslipidemia and regular follow-up lipid panels are mandated, especially when powerful agents such as bexarotene are used. Dietary modification, increased physical activity, and weight management are the cornerstones of initial management for mild hypertriglyceridemia, which is a contributor to cardiovascular risk. More severe impairments (fasting TG > 500 mg/dL) warrant pharmacologic interventions early on to reduce the risk of pancreatitis. Retinoic acid derivative action, lipid metabolism, and treatment of incident dyslipidemias are reviewed to empower prescribers in management of adverse lipid effects.

    Original languageEnglish (US)
    Pages (from-to)404-410
    Number of pages7
    JournalDermatologic Therapy
    Issue number5
    StatePublished - Sep 2013


    • drug-induced dyslipidemia
    • retinoid
    • rexinoid
    • secondary hypertriglyceridemia

    ASJC Scopus subject areas

    • Dermatology

    Fingerprint Dive into the research topics of 'Oral retinoids and plasma lipids'. Together they form a unique fingerprint.

  • Cite this